Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) Director David P. Meeker sold 4,555 shares of the firm's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $2.93, for a total transaction of $13,346.15. Following the completion of the transaction, the director now directly owns 352,489 shares in the company, valued at approximately $1,032,792.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Trevi Therapeutics Stock Performance

Shares of TRVI stock traded down $0.04 during midday trading on Thursday, reaching $2.91. 110,076 shares of the company were exchanged, compared to its average volume of 236,157. The company's 50 day moving average price is $2.83 and its two-hundred day moving average price is $2.83. The company has a market cap of $211.24 million, a P/E ratio of -8.56 and a beta of 1.00. Trevi Therapeutics, Inc. has a 12 month low of $0.97 and a 12 month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter last year, the business earned ($0.07) EPS. As a group, sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TRVI shares. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 8th. Rodman & Renshaw started coverage on Trevi Therapeutics in a research report on Thursday, June 13th. They issued a "buy" rating and a $7.00 target price on the stock. Finally, EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a "strong-buy" rating in a report on Monday, August 19th.

Institutional Trading of Trevi Therapeutics

A number of hedge funds have recently modified their holdings of the business. American Century Companies Inc. raised its position in Trevi Therapeutics by 17.1% during the second quarter. American Century Companies Inc. now owns 54,108 shares of the company's stock valued at $161,000 after buying an additional 7,902 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock valued at $73,000 after purchasing an additional 11,450 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics in the first quarter worth approximately $47,000. Hsbc Holdings PLC acquired a new stake in shares of Trevi Therapeutics during the second quarter worth approximately $61,000. Finally, Rhumbline Advisers grew its position in Trevi Therapeutics by 44.8% during the second quarter. Rhumbline Advisers now owns 75,218 shares of the company's stock valued at $224,000 after purchasing an additional 23,263 shares in the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.